Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Non-Current Liabilities: 2011-2020

Historic Other Non-Current Liabilities for Niagen Bioscience (NAGE) over the last 6 years, with Jun 2020 value amounting to $250,000.

  • Niagen Bioscience's Other Non-Current Liabilities fell 14.68% to $250,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $250,000, marking a year-over-year decrease of 14.68%. This contributed to the annual value of $169,000 for FY2019, which is 38.55% down from last year.
  • Niagen Bioscience's Other Non-Current Liabilities amounted to $250,000 in Q2 2020, which was up 5.04% from $238,000 recorded in Q1 2020.
  • Over the past 5 years, Niagen Bioscience's Other Non-Current Liabilities peaked at $503,850 during Q3 2017, and registered a low of $155,000 during Q3 2018.
  • In the last 3 years, Niagen Bioscience's Other Non-Current Liabilities had a median value of $244,000 in 2020 and averaged $239,100.
  • Per our database at Business Quant, Niagen Bioscience's Other Non-Current Liabilities plummeted by 63.28% in 2018 and then surged by 79.70% in 2019.
  • Over the past 5 years, Niagen Bioscience's Other Non-Current Liabilities (Quarterly) stood at $389,010 in 2016, then fell by 19.28% to $314,000 in 2017, then decreased by 12.42% to $275,000 in 2018, then slumped by 38.55% to $169,000 in 2019, then dropped by 14.68% to $250,000 in 2020.
  • Its Other Non-Current Liabilities was $250,000 in Q2 2020, compared to $238,000 in Q1 2020 and $169,000 in Q4 2019.